Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins

Parasite and free-living microorganisms express surface protein containing multiple CXXC motifs (where C is cysteine and X any other amino acid). We have taken advantage of the properties of these molecules to generate efective oral vaccines.
Published in Microbiology
Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

The protozoan parasite Giardia lamblia colonizes the upper small intestine of many vertebrates, but how Giardia survives within this harsh digesting environment is unknown. CXXC-rich Variant-specific Surface Proteins (VSPs) cover the entire surface of Giardia. These proteins are encoded by ~200 genes of the parasite genome, but only one is expressed at any time. Switching the expression of VSPs contributes to parasite escape from the host immune response.

We previously showed that VSP expression is regulated posttranscriptionally by a mechanism similar to RNA interference (RNAi). Silencing key enzymes of the RNAi pathway generated trophozoites expressing the entire repertoire of VSPs (Prucca et al., Nature 2008) and oral immunization with purified VSPs from such cells protected gerbils (Rivero et al., Nature Medicine 2010), dogs and cats (Serradell et al., npgVaccines 2016) against experimental and natural Giardia infections. This confirms the immunogenic importance of VSPs but also reveals that VSPs survive the digestive environment of the gut.

Meanwhile, David KlatzmannĀ“s team was working on the use of Virus-Like Particles (VLPs) as a vaccine platform against several viral infections (Belier et al., Vaccine 2009; Garrone et al., Sci. Transl. Med. 2011; Kirchmeier et al., Clin. Vaccine Immunol. 2014). Together we developed the innovative idea of combining the protective properties of Giardia VSPs with the immunogenic capabilities of VLPs for vaccination by the oral route. We thus generated VLPs decorated with both VSPs and a model surface antigen (i.e. Influenza virus HA). We showed that such VLPs, and not control ones without VSPs, resisted degradation and generated local and systemic, cellular and humoral responses to the flu antigen when administered orally to mice. The robustness of the immune response is emphasized by the fact that orally vaccinated mice were fully protected from a challenge with live Influenza virus and rejected growing tumors expressing HA. The molecular mechanisms explaining this successful oral vaccination are dual. Indeed, we showed that VSPs are not only resistant to proteolytic digestion under the conditions present in the upper small intestine, but also specifically activated TLR-4. Therefore, VSPs are not only protective but also show adjuvant properties.

Like Giardia, VSP-pseudotyped VLPs were stable at variable temperature, which can allow their use in remote areas of the world where vaccine refrigeration is impractical.

These results pave the way to produce stable and efficient oral vaccines that can circumvent the current trends of vaccine hesitance and refusal.

Our report can be found at https://rdcu.be/bhMTb.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Life Sciences > Biological Sciences > Microbiology

Related Collections

With collections, you can get published faster and increase your visibility.

Cancer and aging

This cross-journal Collection invites original research that explicitly explores the role of aging in cancer and vice versa, from the bench to the bedside.

Publishing Model: Hybrid

Deadline: Jul 31, 2024

Applied Sciences

This collection highlights research and commentary in applied science. The range of topics is large, spanning all scientific disciplines, with the unifying factor being the goal to turn scientific knowledge into positive benefits for society.

Publishing Model: Open Access

Deadline: Ongoing